Rucaparib is a PARP inhibitor in Phase II and III clinical trials for advanced ovarian cancer. In December 2016, the Food and Drug Administration granted an accelerated approval for the use of rucaparib "for the treatment of patients with deleterious BRCA mutation (germline and/or somatic)-associated advanced ovarian cancer who have been treated with two or more chemotherapies".
